Literature DB >> 5144516

Hormonal treatment of metastases of renal carcinoma.

B van der Werf-Messing, H A van Gilse.   

Abstract

A series of 33 patients with metastatic renal cancer and evidence of progression of the disease-apart from pulmonary metastases-was treated with hormones (progestogens in 31 cases, androgens in 2 cases) at the Rotterdamsch Radio-Therapeutisch Instituut. Complete or partial spontaneous regression (or non-progression of pulmonary metastases) before hormone treatment was observed in 8 patients (24%). A favourable subjective response to hormone treatment was obtained in 12 patients (36%), while a positive objective response was obtained in 2 (or 3) cases (6-9%).A favourable response was obtained slightly more frequently in men than in women. The hormonal effect was not demonstrably related to any of the following factors: age of the patient, type of progestogen used, the behaviour of concomitant pulmonary metastases, or the presence or absence of the primary growth.The prognosis was unaffected by hormone therapy, but the 2 year survival rate was significantly higher in patients that showed signs of spontaneous regression of pulmonary metastases, as compared with those without these signs.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5144516      PMCID: PMC2008739          DOI: 10.1038/bjc.1971.54

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  3 in total

1.  Androgens in metastatic renal adenocarcinoma.

Authors:  R D Jenkin
Journal:  Br Med J       Date:  1967-02-11

2.  Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma).

Authors:  M L Samuels; P Sullivan; C D Howe
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

3.  The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body.

Authors:  C H Paine; F W Wright; F Ellis
Journal:  Br J Cancer       Date:  1970-06       Impact factor: 7.640

  3 in total
  2 in total

1.  Immunotherapy of human malignancies with immune RNA.

Authors:  J B DeKernion; K P Ramming; Y H Pilch
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Letter: Metastatic kidney cancer treated with multiple drug therapy at the Rotterdam Radiotherapy Institute.

Authors:  B van der Werf-Messing; J Mulder
Journal:  Br J Cancer       Date:  1974-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.